Eight-year median survival in multiple myeloma after total therapy 2: Roles of thalidomide and consolidation chemotherapy in the context of total therapy 1

British Journal of Haematology

Volumn 141, Issue 4, 2008, Pages 433-444

  Zangari, Maurizio ^a   Van Rhee, Frits ^a   Anaissie, Elias ^a   Pineda Roman, Mauricio ^a   Haessler, Jeff ^a   Crowley, John ^a   Barlogie, Bart ^a  

^a NONE

Author keywords

High dose therapy; Multiple myeloma; Prognosis

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 42249095799     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.06982.x     Document Type: Article

References (29)

1. Barlogie, B., Smith, L. Alexanian, R. (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine, 310, 1353 1356.
2. Barlogie, B., Jagannath, S., Vesole, D.H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J. Tricot, G. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789 793.
3. Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D. Tricot, G. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98, 492 494.
4. Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. Crowley, J. (2006a) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 1021 1030.
5. Barlogie, B., Tricot, G., Rasmussen, E., Anaissie, E., van Rhee, F., Zangari, M., Fassas, A., Hollmig, K., Pineda-Roman, M., Shaughnessy, J., Epstein, J. Crowley, J. (2006b) Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood, 107, 2633 2638.
6. Barlogie, B., Tricot, G.J., van Rhee, F., Angtuaco, E., Walker, R., Epstein, J., Shaughnessy, J.D., Jagannath, S., Bolejack, V., Gurley, J., Hoering, A., Vesole, D., Desikan, R., Siegel, D., Mehta, J., Singhal, S., Munshi, N.C., Dhodapkar, M., Jenkins, B., Attal, M., Harousseau, J.L. Crowley, J. (2006c) Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology, 135, 158 164.
7. Cox, D.R. (1972) Regression tables and life tables. Journal of the Royal Statistical Society, 34, 187 202.
8. Desikan, R., Munshi, N., Zangari, M., Badros, A., Anaissie, E., Tricot, G., Lim, S., Ayers, D., Spencer, H., Englehart, J. Barlogie, B. (1999) DCEP consolidation chemotherapy (CC) after 2 cycles of melphalan-based high dose therapy (HDT) - high incidence of CR and superior outcome in comparison with matched historical controls. Blood, 94, 1411a.
9. Facon, T., Mary, J., Harousseau, J.L., Huguet, F., Berthou, C., Grosbois, B., Anglaret, B., Azzedine, A., Rodon, P., Peny, A. Intergroupe Francophone du Myélome 2006) Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Journal of Clinical Oncology, 24, 1 abstract.
10. Gooley, T.A., Leisenring, W., Crowley, J. Storer, B.E. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine, 18, 695 706.
11. Jagannath, S., Durie, B.G., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D. Crowley, J. (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology, 129, 776 783.
12. Kaplan, E. Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457 481.
13. Lee, C.K., Barlogie, B., Munshi, N., Zangari, M., Fassas, A., Jacobson, J., van Rhee, F., Cottler-Fox, M., Muwalla, F. Tricot, G. (2003) DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. Journal of Clinical Oncology, 21, 2732 2739.
14. Mateos, M.V., Hernandez, J.M., Hernandez, M.T., Gutierrez, N.C., Palomera, L., Fuertes, M., Diaz-Mediavilla, J., Lahuerta, J.J., de la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., de Arriba, F., Alegre, A., Oriol, A., Carrera, D., Garcia-Larana, J., Garcia-Sanz, R., Blade, J., Prosper, F., Mateo, G., Esseltine, D.L., van de Velde, H. San Miguel, J.F. (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 108, 2165 2172.
15. Oakervee, H.E., Popat, R., Curry, N., Smith, P., Morris, C., Drake, M., Agrawal, S., Stec, J., Schenkein, D., Esseltine, D.L. Cavenagh, J.D. (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology, 129, 755 762.
16. Orlowski, R.Z., Voorhees, P.M., Garcia, R.A., Hall, M.D., Kudrik, F.J., Allred, T., Johri, A.R., Jones, P.E., Ivanova, A., Van Deventer, H.W., Gabriel, D.A., Shea, T.C., Mitchell, B.S., Adams, J., Esseltine, D.L., Trehu, E.G., Green, M., Lehman, M.J., Natoli, S., Collins, J.M., Lindley, C.M. Dees, E.C. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, 3058 3065.
17. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., Catalano, L., Zamagni, E., Petrucci, M.T., De Stefano, V., Ceccarelli, M., Ambrosini, M.T., Avonto, I., Falco, P., Ciccone, G., Liberati, A.M., Musto, P. Boccadoro, M. (2006a) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 367, 825 831.
18. Palumbo, A., Falco, P., Falcone, A., Corradini, P., Di Raimondo, F., Giuliani, N., Rossi, G., Morabito, F., Canepa, L., Gozzetti, A., Ambrosini, M.T., Zeldis, J., Knight, R., Foà, R., Boccadoro, M. Petrucci, M.T. (2006b) Oral Revlimid® plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II study. Blood (ASH Annual Meeting Abstracts), 108, 100.
19. Palumbo, A., Ambrosini, M.T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., Bringhen, S., Falco, P., Avonto, I., Cavallo, F. Boccadoro, M. (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 109, 2767 2772.
20. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431 436.
21. Ramasamy, K., Branford, R., Selvaratnam, R., Ho, A., Duarte, R., Devereux, S., Pagliuca, A. Mufti, G. (2004) Analysis of beam (Carmustine, Etoposide, Cytosine Arabinoside, Melphalan) versus high dose melphalan (HDM) with autologous rescue in multiple myeloma (MM). Blood, 104, 5227.
22. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609 2617.
23. Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., Schlossman, R.L., Rajkumar, S.V., Desikan, K.R., Hideshima, T., Munshi, N.C., Kelly-Colson, K., Doss, D., McKenney, M.L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W.S., Zeldis, J., Knight, R., Weller, E. Anderson, K.C. (2006a) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, 3458 3464.
24. Richardson, P., Jagannath, S., Avigan, D., Alsina, M., Schlossman, R., Mazumder, A., Munshi, N., Ghobrial, I., Doss, D., McKenney, M., Farrell, M., Mitsiades, C., Hideshima, T., Byrne, C., Knight, R., Birner, A., Myers, T., Weller, E. Anderson, K.C. (2006b) Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Blood (ASH Annual Meeting Abstracts), 108, 405.
25. Sawyer, J., Waldron, J., Jagannath, S. Barlogie, B. (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics, 82, 41 49.
26. Shaughnessy, Jr., J.D., Zhan, F., Burington, B.E., Huang, Y., Colla, S., Hanamura, I., Stewart, J.P., Kordsmeier, B., Randolph, C., Williams, D.R., Xiao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S.G., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. Barlogie, B. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 2276 2284.
27. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565 1571.
28. Wang, M., Delasalle, K., Giralt, S. Alexanian, R. (2005) Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood (ASH Annual Meeting Abstracts), 106, 784.
29. Weber, D., Rankin, K., Gavino, M., Delasalle, K. Alexanian, R. (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology, 21, 16 19.